研報掘金丨華安證券:維持甘李藥業“買入”評級,海外市場保持高增長
華安證券研報指出,甘李藥業(603087.SH)2024年歸母淨利潤6.15億元,同比增長80.75%;2025年一季度歸母淨利潤3.12億元,同比增長224.90%。2025Q1業績亮眼,國內量價齊升,海外市場保持高增長。出海進展順利,公司胰島素全球佈局初見雛形。同時,公司加速國際團隊建設,根據不同地區和國家的市場需求,實施精準的市場投資、本土分銷策略,全力開拓國際化多元市場。在歐美市場,公司與山德士的合作仍在持續穩步的推進。創新產品管線有序推進,公司另一款核心產品GZR4注射液在中國開展用於治療2型糖尿病的3 項III 期臨牀研究——SUPER-1(胰島素初治)、SUPER-2(基礎胰島素經治)及SUPER-3(基礎胰島素聯合餐時胰島素強化治療)均完成首例受試者給藥。維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.